Clinical Trials
26 trialsMK-3475-06C
Merck Sharp & Dohme LLC
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
Neo-CD
Second Affiliated Hospital, School of Medicine, Zhejiang University
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
OrigAMI-1
Janssen Research & Development, LLC
TNTIT
Fudan University
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
PANGEA
UNC Lineberger Comprehensive Cancer Center
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
MK-3475-06E
Merck Sharp & Dohme LLC
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Zhejiang Doer Biologics Co., Ltd.
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NEO-CLAUD
Asan Medical Center
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
HAICI
Zhejiang Cancer Hospital
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
Fujian Cancer Hospital
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Chinese PLA General Hospital
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.